The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Sprt Regulatory News (SIS)

Share Price Information for Science Sprt (SIS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.226%)
Open: 15.75
High: 15.75
Low: 15.75
Prev. Close: 15.75
SIS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conclusion of Strategic Review and Trading Update

13 Apr 2023 07:00

RNS Number : 0376W
Science in Sport PLC
13 April 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

 

Science in Sport plc

("Science in Sport", the "Company" or the "Group")

 Conclusion of Strategic Review and Trading Update

Science in Sport, the premium performance nutrition company serving elite athletes, sports enthusiasts, and the active lifestyle community, announces the conclusion of its strategic review, which was initiated on 30 September 2022 (the "Strategic Review"). 

Although 2022 started positively, the Group was adversely impacted during April 2022 onwards by a combination of the rapid global increase in input costs and a levelling off in market growth. This coincided with a period of peak investment in new supply chain facilities designed to support future growth and resulted in a market capitalisation that the Board believed undervalued the Company and failed to recognise the inherent value of its premium brands and strong market position.

Strategic Review conclusion 

 

Following the Strategic Review, the Board has concluded that shareholders' interests are best served by seeking to maximise value through focusing on accelerating the profitable growth of the business under an ambitious growth and efficiency plan that is currently delivering in line with management's expectations. 

 

The Board's decision is consistent with that of the independent corporate adviser appointed to advise on the Strategic Review.

The key drivers of the Board's decision are: 

 

· Renewal of growth trajectory that saw Science in Sport CAGR brand sales growth from 2012 to 2021 of 23%;

 

· A high level of confidence that the business model, operational and marketing assets and strategy will provide long term profitable growth in global markets;

 

· A high level of confidence in the Board's comprehensive prioritised profitable growth plan to build progressively to industry profitability benchmarks; and 

 

· Trading in the year to date, as further noted below, indicates that the business is responding well to the new plan, with growth across both different geographies and sales channels, price increases, and lower costs attributed to the recently commissioned manufacturing and distribution facility, all contributing to improved profitability.

 

Business model

 

The Company owns two strong brands in complementary market sectors and the review validated the significant differentiation and superiority of both brands compared to the competition and their ability to attract new users and retain loyalty.

 

Brand strength has been built by the significant in-house scientific capability which has provided a long-term pipeline of advanced products that attracts Elite athletes competing in world level events including the Olympic games and World and National championships. The Company has an ever-expanding roster of contracted renowned global level athletes believed to be one of the most expansive in the industry, who provide persuasive influence of product superiority in media campaigns. 

 

The Company has an omnichannel route to market, including an industry exclusive partnership with the Amazon-favoured Flywheel Digital organisation, as well as expanding distribution partnerships in China and the USA. The business has historically had and retains a very strong retail capability in its important UK market.

 

To deliver increased profitable growth in the long run, the Company has completed its investment in a state-of-the-art fully integrated supply chain facility including warehousing, manufacturing, distribution, and administrative offices in Blackburn.

 

The cost benefits of the facility, now being delivered, are expected to provide operational leverage and expansion capacity over the foreseeable future for continued operationally leveraged global growth.

 

Comprehensive Profitable Growth Plan

 

The Board has agreed a business plan which has been developed to regain growth levels of former years and step change margins to build profitability to industry benchmarks.

 

The global £18.7bn Sports Nutrition market is regaining its momentum and is forecast to grow at its historic rate of almost 10% per annum over the next five years and, importantly, the Company has implemented price increases to offset the global industry cost increases experienced in the past year.

 

For purposes of channel growth, and an improved margin plan to capitalise on this growth opportunity there is a focus on a category exclusive partnership with the Amazon-favoured Flywheel Digital, a new exclusive distribution partner, The Feed, in the large USA market, and significantly strengthened distribution in APAC.

 

The Board has developed an expansion plan for the rapidly growing Chinese market where Science in Sport GO Gels have recently been launched, leveraging the distribution platform of the already successful and growing PHD business. Marking the launch, Science in Sport is the official nutrition sponsor of the widely publicised Shanghai Marathon. 

 

The new Blackburn distribution facility is expected to significantly expand margins due to its market leading low operating costs. The Company has installed a new highly efficient bar line taking all bar production in-house. The line is fully operational and is expected to be a significant contributor to the anticipated improvement in profitability.

 

Current Trading

 

The Group has had a good start to FY23 with Q1 revenue of £15.6m delivering growth of 2.3% compared to the prior year. While January and February were affected by Amazon global destocking and COVID in China, momentum is gathering, as evidenced by a record March revenue of £7.2m (FY22 £6.4m) and current trading performance in April.

 

Q1 trading contribution margin was 20.9% (FY22 13.7%), delivering a significant improvement over the comparative period, because of the implementation of the growth plan. Overheads were in line with management expectations.

 

A further trading update will be given when the Company announces the 2022 annual results prior to the end of Q2 FY23.

 

Review Concludes

The Board confirms that it is not in receipt of any approaches for the Company at the date of this announcement.

With the conclusion of the Strategic Review, the Company is no longer in an "offer period" as defined by the City Code on Takeovers and Mergers (the "Takeover Code") and the disclosure requirements pursuant to Rule 8 of the Takeover Code are no longer applicable

For further information:

 

Science in Sport plc

T: 020 7400 3700

Stephen Moon, CEO

Daniel Lampard, CFO

 

Liberum (Nominated Adviser and Broker)

T: 020 3100 2000

Richard Lindley

William Hall

Lucas Bamber

 

 

Notes to Editors:

 

About Science in Sport plc

 

Headquartered in London, Science in Sport plc is a leading sports nutrition business that develops, manufactures, and markets innovative nutrition products for professional athletes, sports and fitness enthusiasts and the active lifestyle community. The Company has two highly regarded brands, PhD Nutrition, a premium active-nutrition brand targeting the active lifestyle community, and SiS, a leading endurance nutrition brand among elite athletes and professional sports teams.

 

The two brands sell through the Company's phd.com and scienceinsport.com digital platforms, third-party online sites, including Amazon and Tmall, and extensive retail distribution in the UK and internationally, including major supermarkets, high street chains and specialist sports retailers. This omnichannel footprint enables the Company to address the full breadth of the sports nutrition market, worth $42.9bn in 2022 and forecast to grow CAGR 7.4% from 2023 to 2030.1

 

PhD is one of the UK's leading active nutrition brands with a reputation for high quality and product innovation. The brand has grown rapidly since its launch in 2005. The range now comprises powders, bars, and supplements, including the high protein, low sugar range, PhD Smart. PhD brand ambassadors include leading endurance and strength athlete Ross Edgley and influencer Gabby Allen. 

 

SiS, a leading endurance nutrition business founded in 1992, has a core range comprising gels, powders and bars focused on energy, hydration, and recovery. SiS is an official endurance nutrition supplier to over 320 professional teams, organisations, and national teams worldwide. SiS supplies more than 150 professional football clubs in the UK, Europe, and the USA.

 

SiS is Performance Solutions partner to Ineos Grenadiers cycling team, and Tottenham Hotspur and CGC Nice football clubs, as well as Official Nutrition Partner to the Milwaukee Bucks, 2021 National Basketball Association Champions. 

 

For further information, please visit phd.com and scienceinsport.com

 

Grand View Research (2022)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAPLAFLPDEFA
Date   Source Headline
18th Jan 20184:41 pmRNSIssue of Equity
18th Jan 20187:00 amRNSSiS becomes Official Partner of Manchester United
17th Jan 20183:44 pmRNSHolding(s) in Company
16th Jan 20187:00 amRNSPre-Close Trading Update
6th Dec 20174:47 pmRNSHolding(s) in Company
6th Dec 201710:29 amRNSHolding(s) in Company
6th Dec 201710:27 amRNSHolding(s) in Company
6th Dec 201710:20 amRNSHolding(s) in Company
5th Dec 20177:00 amRNSHolding(s) in Company
4th Dec 20171:22 pmRNSDirector/PDMR Shareholding
1st Dec 201712:44 pmRNSResults of General Meeting and Open Offer
14th Nov 20177:00 amRNSFirm Placing and Open Offer
27th Oct 20177:00 amRNSSiS announces partnership with Rock 'n' Roll
27th Oct 20177:00 amRNSSiS announces three-year deal with USA Triathlon
20th Sep 20179:06 amRNSHalf-year Report - Replacement
20th Sep 20177:00 amRNSHalf-year Report
12th Sep 20172:43 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSTHREE MORE YEARS FOR SiS AND TEAM SKY
4th Aug 20177:00 amRNSSIS to fuel leading British football clubs
3rd Aug 20177:00 amRNSNotice of Results
20th Jul 20177:00 amRNSHalf Year Trading Update
26th Jun 20174:30 pmEQSCavendish Asset Management: Paul Mumford named Small Cap Awards' Fund Manager of the Year
26th Jun 201712:29 pmRNSDirector/PDMR Shareholding
21st Jun 201712:44 pmRNSResult of AGM
20th Jun 20178:00 amRNSPDMR Dealing
15th Jun 20177:00 amRNSSIS to fuel British Triathlon
30th May 20177:00 amRNSSIS granted patent for novel WHEY20
19th May 20175:17 pmRNSPosting of Annual Report
18th May 20177:00 amRNSSIS to Fuel Cycling Australia To Tokyo 2020
12th May 20179:00 amRNSHolding(s) in Company
3rd May 20179:23 amRNSHolding(s) in Company
23rd Mar 20171:00 pmRNSPDMR Dealings and Issue of Equity
23rd Mar 20177:00 amRNSFinal Results
2nd Mar 20179:15 amRNSTotal Voting Rights
19th Jan 20178:44 amRNSHolding(s) in Company
17th Jan 20177:00 amRNSSIS Extends World Class Banned Substance Testing
10th Jan 20177:00 amRNSSIS To Fuel British Cycling To Tokyo 2020
9th Jan 20175:24 pmRNSIssue of Equity
5th Jan 20177:00 amRNSPre-Close Trading Update
29th Nov 20167:00 amRNSSiS receives award from Investors in People
17th Nov 20167:00 amRNSDirector/PDMR Shareholding
16th Nov 20167:00 amRNSDirector/PDMR Shareholding
27th Oct 20167:00 amRNSDirector/PDMR Shareholding
18th Oct 20167:00 amRNSAppointment of US Country Manager
26th Sep 20164:09 pmRNSNew Long Term Incentive Plan
22nd Sep 20167:00 amRNSHalf Yearly Report
21st Sep 20162:45 pmRNSAppointment of Non-Executive Director
1st Sep 20167:00 amRNSTwo New Senior Appointments
30th Aug 20167:00 amRNSOfficial Sports Nutrition Partner to Liverpool FC
25th Aug 20162:04 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.